Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a global commercial-stage biopharmaceutical company pioneering the development and commercialization of ribonucleic acid interference, or RNAi, therapeutics. Founded in 2002, Alnylam translates RNAi science into innovative medicines that silence disease-causing genes by… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alnylam Pharmaceuticals, Inc. does
In the company’s own words
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a global commercial-stage biopharmaceutical company pioneering the development and commercialization of ribonucleic acid interference, or RNAi, therapeutics. Founded in 2002, Alnylam translates RNAi science into innovative medicines that silence disease-causing genes by targeting messenger RNA before proteins are produced. The company's website is www.alnylam.com.
Alnylam has achieved a significant milestone by bringing six first-in-class RNAi-based medicines to market: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), Leqvio (inclisiran, commercialized by Novartis), and Qfitlia (fitusiran, commercialized by Sanofi). These approved products address rare and prevalent diseases across multiple therapeutic areas including transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, hypercholesterolemia, and hemophilia.
The company operates a robust pipeline of more than twenty clinical programs spanning late-stage and early-stage development. Notable investigational programs include nucresiran for ATTR amyloidosis, zilebesiran for hypertension developed in collaboration with Roche, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and cemdisiran for complement-mediated diseases developed with Regeneron.
Alnylam's technology platform encompasses multiple delivery approaches optimized for different tissues. The company utilizes N-acetylgalactosamine (GalNAc) conjugates for hepatic delivery, lipid nanoparticles for systemic delivery, and hexadecyl (C16) conjugates for central nervous system and ocular delivery. Advanced platforms including ESC+, IKARIA, and GEMINI technologies enable enhanced potency, durability, and multi-target capabilities.
The company pursues a disciplined research strategy targeting genetically validated genes with high unmet medical need, early biomarkers, and clear development pathways. Alnylam has established strategic collaborations with major pharmaceutical companies including Novartis, Sanofi, Roche, and Regeneron to co-develop and commercialize select programs globally. In 2026, the company launched its Alnylam 2030 strategy, aspiring to achieve TTR market leadership, deliver multiple blockbuster medicines beyond TTR, expand to ten tissue types, and achieve sustained profitable growth through disciplined innovation and commercial execution.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1178670
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alnylam Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alnylam Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Alnylam Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Alnylam Pharmaceuticals, Inc.’s debt, $154.25M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.46%, maturing 2027 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alnylam Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alnylam Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alnylam Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”